Evercore ISI Group Maintains In-Line on Inspire Medical Systems, Lowers Price Target to $60
Evercore ISI Group analyst Daniel Markowitz maintains Inspire Medical Systems (NYSE:INSP) with a In-Line and lowers the price target from $72 to $60.
Share
Why It Matters
An expert analyst thinks Inspire Medical is fairly priced but worth less than before. This means the company might face slower growth or higher costs ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.